Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million)
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES OR REQUIRE REGISTRATION OR OTHER ACTIONS. PLEASE REFER TO THE SECTION “IMPORTANT INFORMATION” BELOW.
Arcoma AB (“Arcoma” or the “Company”) (Nasdaq First North Growth Market: ARCOMA) today announces that the Board of Directors has resolved on a directed share issue of a total of 1,122,950 new shares (the “New Shares”) for the funds managed by Eiffel Investment Group, based on the authorization granted by the Annual General Meeting held on 14 May 2025 (the “Directed Share Issue”). Through the Directed Share Issue, the Company will raise approximately 11.0 MSEK before transaction-related costs.
The Directed Share Issue
The Board of Directors of Arcoma has today resolved on the Directed Share Issue of 1,122,950 New Shares, based on the authorization from the Annual General Meeting on 14 May 2025. The issue has been fully subscribed by the funds FCPI Alto Innovation 2021 and FCPI Alto Innovation 2023 managed by the French institutional investor Eiffel Investment Group (“Eiffel”), which will thereby become one of Arcoma’s largest shareholders. The subscription price for the New Shares is 9.76 SEK per share, corresponding to a premium of approximately 4.3 percent compared to the closing price of Arcoma’s shares on Nasdaq First North Growth Market on 24 June 2025.
Through the Directed Share Issue, the Company will raise approximately 11.0 MSEK before transaction-related costs. Arcoma intends to use the net proceeds to expand its sales resources, invest further in product development and innovation, and accelerate its acquisition strategy.
Mattias Leire, CEO, Arcoma comments:
“We are very pleased to welcome Eiffel Investment Group as a new strategic shareholder in Arcoma. That an internationally recognized investor with deep expertise in innovation chooses to invest in our company is a strong vote of confidence in our strategy and business model. Eiffel initiated the dialogue after following our progress and expressing appreciation for how we have strategically built a scalable business model. They have particularly highlighted our ability to translate this strategy into tangible results, through improved profitability, a strengthened balance sheet, and a clear path toward long-term value creation. This confirms that our methodical approach is appreciated by investors who share our view on sustainable growth. With this capital injection, we are accelerating our growth journey. We will strengthen our market presence through expanded sales resources, continue investing in product development and innovation, and actively accelerate our acquisition efforts. The combination of a strengthened financial position and a new strategic owner provides the right conditions to realize Arcoma’s full potential.”
Reasons for the deviation from shareholders’ preferential rights and basis for the subscription price
In preparing the Directed Share Issue, the Board of Directors has made a comprehensive assessment and carefully evaluated the possibility of raising capital through a rights issue with preferential rights for existing shareholders. In its evaluation, the Board of Directors concluded that:
- The Directed Share Issue brings in a new major shareholder in the form of Eiffel, strengthening the Company’s shareholder base with an international, institutional, and long-term investor who can contribute to the Company’s continued growth. The Board of Directors believes this significantly enhances the Company’s ownership structure. Furthermore, it is considered particularly advantageous to secure financing from an institutional and professional investor on favorable terms.
- A rights issue would be significantly more time- and resource-consuming compared to the Directed Share Issue, especially due to the work involved in securing such an issue, with no guarantee of full subscription. A shorter timeline provides flexibility for potential short-term investment opportunities, reduces exposure to market volatility, and allows the Company to capitalize on current interest in its shares. Additionally, the costs associated with the Directed Share Issue are expected to be significantly lower than those of a rights issue, which would likely require the procurement of a guarantee consortium. The Directed Share Issue has been executed swiftly and cost-effectively through the Company’s dedicated efforts.
Considering the above, the Board of Directors has concluded that a directed share issue with deviation from shareholders’ preferential rights is the most advantageous option for Arcoma, creates value for the Company, and is in the best interest of its shareholders.
The Board of Directors has placed great emphasis on ensuring that the subscription price is in line with market conditions relative to the current share price. The subscription price for the New Shares is 9.76 SEK per share, corresponding to a premium of approximately 4.3 percent compared to the closing price of Arcoma’s shares on Nasdaq First North Growth Market on 24 June 2025. The subscription price has been determined through arm’s length negotiations with the participating investor.
Given that the subscription price was negotiated with an external institutional investor, that it represents a premium, and that investors have recently had the opportunity to purchase shares on the market at a lower price, the Board of Directors considers the subscription price to be market-based and highly favorable for the Company and its shareholders.
Dilution and number of new shares
Through the Directed Share Issue, the number of outstanding shares and votes in the Company will increase by 1,122,950 shares, from 13,185,560 shares to 14,308,510 shares, and the share capital will increase from SEK 26,371,120.0 to 28,617,020.0 SEK. The Directed Share Issue entails a dilution of approximately 7.8 percent of the number of shares and votes in the Company.
About Arcoma
With extensive industry experience, Arcoma is a leading provider of integrated digital X-ray systems featuring high quality and advanced technology. Arcoma’s products offer the latest in digital imaging technology combined with technically advanced motorized positioning systems, which—together with ergonomic Scandinavian design—provide customers with complete, configurable, and functional digital X-ray systems. The Company’s products are sold through distributors and OEM customers, and there are currently over 3,500 Arcoma X-ray systems installed worldwide. Arcoma is listed on Nasdaq First North.
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ).
For more information about the company, please visit: www.Arcoma.se
For further information, please contact:
Mattias Leire, CEO, mattias.leire@Arcoma.se, 0766-66 54 88
For more IR-related information and to subscribe to press releases, please visit our investor page: www.Arcoma.se/about-us/investors/
This information is such that Arcoma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the CEO, on 24 June 2025 at 7:15 PM CEST.
Important information
Publication, distribution or release of this press release may, in certain jurisdictions, be subject to restrictions by law and the persons in such jurisdictions where this press release has been published or distributed should inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the Company in any jurisdiction where such an offer or solicitation would be illegal. In each Member State of the European Economic Area (“EEA”), this press release is directed only to “qualified investors” in the Member State in accordance with the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”) definition.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, Switzerland, the United States, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.
In the United Kingdom, this document, and any other material relating to the securities referred to herein, is only being distributed to, and is only directed at, and any investment or investment activity attributable to this document is only available to, and will be engaged in only by, “qualified investors” as defined as (i) professional investors as set out in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) fall within Article 49(2)(a) to (d) (“entities with high net worth” etc.) of the Order, (all such persons together being referred to as “Relevant Persons”). An investment or investment activity to which this communication relates in the United Kingdom is available only to Relevant Persons and will only be carried out with Relevant Persons. Persons that are not Relevant Persons should not take any action based on this press release and should not act or rely on it.
This press release is not a prospectus for the purposes of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorised any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Share Issue. This press release neither identifies nor claims to identify risks (direct or indirect) which could be associated with an investment in new shares. An investment decision to acquire or subscribe for new shares in the Directed Share Issue may only be made based on publicly available information.
Forward-looking statements
This press release contains forward-looking statements that reflect the Company’s intentions, assessments, or current expectations about and targets for the Company’s future results of operations, financial condition, development, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by the fact that they contain words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Even if the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements, which are a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as of its date and are subject to change without notice. Neither the Company nor anyone else does undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or Nasdaq First North Growth markets rule book for issuers.
Attachment
- PR Directed Issue
- Allot Announces Pricing of UnderwrittenPublic Offering of Ordinary Shares - June 24, 2025
- Air Methods Expands Bell 429 Fleet to Support Partners - June 24, 2025
- Cidara Announces Pricing of Upsized Public Offering of Common Stock - June 24, 2025
